CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Royalties	$ 47,236	$ 51,301	$ 207,869	$ 222,931
Diagnostic services	37,978	6,026	69,558	10,712
Clinical research services	3,900	0	35,573	0
Total revenues	89,114	57,327	313,000	233,643
Costs and expenses:
Cost of revenues	424,559	173,537	1,143,293	429,992
Research and development	3,937,398	2,546,533	11,221,876	7,428,349
Selling and marketing	2,940,862	1,798,263	9,127,450	4,508,766
General and administrative	2,710,782	1,948,546	9,183,761	5,756,047
Total operating expenses	10,013,601	6,466,879	30,676,380	18,123,154
Loss from operations	(9,924,487)	(6,409,552)	(30,363,380)	(17,889,511)
Net interest expense	(354,993)	(335,359)	(967,522)	(1,100,080)
Gain (loss) from change in fair value of derivative financial instruments — warrants	88,208	4,017,212	674,834	(1,105,270)
Other income (loss), net	0	(8,130)	0	4,617
Net loss	(10,191,272)	(2,735,829)	(30,656,068)	(20,090,244)
Preferred stock dividend	(6,060)	(6,060)	(18,180)	(18,180)
Net loss attributable to common stockholders	$ (10,197,332)	$ (2,741,889)	$ (30,674,248)	$ (20,108,424)
Net loss per common share - basic (in USD per share)	$ (0.34)	$ (0.10)	$ (1.02)	$ (0.80)
Net loss per common share - diluted (in USD per share)	$ (0.34)	$ (0.23)	$ (1.04)	$ (0.96)
Weighted average shares outstanding — basic	30,339,774	28,560,211	30,018,841	25,014,966
Weighted average shares outstanding — diluted	30,339,774	29,128,235	30,136,572	25,204,307